Esperion Therapeutics, Inc. (ESPR)
PHARMACEUTICAL PREPARATIONS
Esperion Therapeutics, Inc. (ESPR) was listed on Nasdaq from June 26, 2013 and stopped trading under the symbol ESPR on July 14, 2026.
- Listed On
- Nasdaq
- Listed Since
- June 26, 2013
- Stopped Trading
- July 14, 2026
- Employees
- 294
About Esperion Therapeutics, Inc.
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 184 institutions reported holding ESPR, with 204.9 million shares worth $645.8 million in aggregate. The largest reported holder was Glazer Capital, with 22.4 million shares worth $70.8 million. Of the 5 largest holders listed below, 2 opened new positions in ESPR and 3 added shares during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Glazer Capital | 22,416,339 | $71M | New position |
| BlackRock | 22,128,021 | $70M | Added 23.95% |
| Vanguard | 15,744,764 | $50M | Added 0.34% |
| Trium Capital | 11,158,150 | $35M | New position |
| Goldman Sachs | 10,380,646 | $33M | Added 330.65% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ESPR?
Esperion Therapeutics, Inc. (ESPR) was listed on Nasdaq from June 26, 2013 and stopped trading under the symbol ESPR on July 14, 2026.
Who are the largest institutional holders of ESPR?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ESPR were Glazer Capital, BlackRock and Vanguard.
How many institutions own ESPR?
184 institutions reported a position in ESPR for the quarter ended June 30, 2026, worth $645.8 million in total.
Did institutions buy or sell ESPR last quarter?
Of the 5 largest reported holders, 2 opened new positions in ESPR and 3 added shares during the quarter. Every reported holder and its change is on the SentiSense ownership page for ESPR.
Every reported institutional holder, plus insider and congressional trades in ESPR, on SentiSense.